Docetaxel in advanced non-small cell lung cancer

Heather Wakelee, Sakkaraiappan Ramalingam, Chandra P. Belani

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Based on the survival benefit demonstrated in large randomized clinical trials, docetaxel is approved for the treatment of advanced non-small cell lung cancer (NSCLC) in both the first- and second-line settings. The efficacy of docetaxel in combination with cisplatin is equivalent to some, and superior to other, platinum-based doublets for first-line management of NSCLC, and has a manageable toxicity profile. Carboplatin-based regimens and nonplatinum combinations with docetaxel also have proven efficacy in first-line therapy of patients with advanced NSCLC. Combinations of docetaxel with various novel targeted agents have produced encouraging data in Phase II studies. This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)13-24
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume5
Issue number1
DOIs
StatePublished - Feb 2005

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Carboplatin
Platinum
Cisplatin
Randomized Controlled Trials
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Wakelee, Heather ; Ramalingam, Sakkaraiappan ; Belani, Chandra P. / Docetaxel in advanced non-small cell lung cancer. In: Expert Review of Anticancer Therapy. 2005 ; Vol. 5, No. 1. pp. 13-24.
@article{6c3c32d3c4594956a8d4802d355556ee,
title = "Docetaxel in advanced non-small cell lung cancer",
abstract = "Based on the survival benefit demonstrated in large randomized clinical trials, docetaxel is approved for the treatment of advanced non-small cell lung cancer (NSCLC) in both the first- and second-line settings. The efficacy of docetaxel in combination with cisplatin is equivalent to some, and superior to other, platinum-based doublets for first-line management of NSCLC, and has a manageable toxicity profile. Carboplatin-based regimens and nonplatinum combinations with docetaxel also have proven efficacy in first-line therapy of patients with advanced NSCLC. Combinations of docetaxel with various novel targeted agents have produced encouraging data in Phase II studies. This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC.",
author = "Heather Wakelee and Sakkaraiappan Ramalingam and Belani, {Chandra P.}",
year = "2005",
month = "2",
doi = "10.1586/14737140.5.1.13",
language = "English (US)",
volume = "5",
pages = "13--24",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

Docetaxel in advanced non-small cell lung cancer. / Wakelee, Heather; Ramalingam, Sakkaraiappan; Belani, Chandra P.

In: Expert Review of Anticancer Therapy, Vol. 5, No. 1, 02.2005, p. 13-24.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Docetaxel in advanced non-small cell lung cancer

AU - Wakelee, Heather

AU - Ramalingam, Sakkaraiappan

AU - Belani, Chandra P.

PY - 2005/2

Y1 - 2005/2

N2 - Based on the survival benefit demonstrated in large randomized clinical trials, docetaxel is approved for the treatment of advanced non-small cell lung cancer (NSCLC) in both the first- and second-line settings. The efficacy of docetaxel in combination with cisplatin is equivalent to some, and superior to other, platinum-based doublets for first-line management of NSCLC, and has a manageable toxicity profile. Carboplatin-based regimens and nonplatinum combinations with docetaxel also have proven efficacy in first-line therapy of patients with advanced NSCLC. Combinations of docetaxel with various novel targeted agents have produced encouraging data in Phase II studies. This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC.

AB - Based on the survival benefit demonstrated in large randomized clinical trials, docetaxel is approved for the treatment of advanced non-small cell lung cancer (NSCLC) in both the first- and second-line settings. The efficacy of docetaxel in combination with cisplatin is equivalent to some, and superior to other, platinum-based doublets for first-line management of NSCLC, and has a manageable toxicity profile. Carboplatin-based regimens and nonplatinum combinations with docetaxel also have proven efficacy in first-line therapy of patients with advanced NSCLC. Combinations of docetaxel with various novel targeted agents have produced encouraging data in Phase II studies. This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=14244255859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244255859&partnerID=8YFLogxK

U2 - 10.1586/14737140.5.1.13

DO - 10.1586/14737140.5.1.13

M3 - Review article

C2 - 15757434

AN - SCOPUS:14244255859

VL - 5

SP - 13

EP - 24

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -